Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
Business Wire•22/10/2026•08:00 ET
0
Key Highlights
- ➤Datavault AI plans 19.9% fully diluted DataMEDS equity stake for expanded technology license
- ➤DataMEDS assumes commercialization costs under the proposed capital-efficient licensing structure
- ➤Non-binding LOI targets fourth quarter 2026 closing after due diligence and definitive agreements
- ➤Expanded license covers patient-controlled healthcare data access, monetization, and tokenization technologies
- ➤Datavault AI may receive royalties and designate one DataMEDS board director after closing
Expert Statements
Nathaniel Bradley, CEO of Datavault AI
“DataMEDS will reduce the cost, improve the quality of care and empower the patients with powerful data-driven outcomes. This is an enduring vision of true pioneers in behavioral healthcare. Datavault AI is excited to be able to meaningfully participate in the value creation at MEDS via equity participation and royalties for the use of our technologies”
Nathaniel Bradley, CEO of Datavault AI
“Given the significant amount of due diligence and document preparation that has already taken place under the previous LOI, we believe a fourth quarter 2026 closing is realistic. We look forward to supporting DataMEDS as it seeks to disrupt healthcare through its ability to create good health outcomes.”
Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
Expanded healthcare platform would bring together patient-controlled data tokenization, biometric medication verification, and automated delivery technologies
Get started
Create a free account to read the full story.